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Abstract
Background: The effects of renal denervation on cardiovascular reflexes and markers of nephropathy in diabetic-
hypertensive rats have not yet been explored.
Methods: Aim: To evaluate the effects of renal denervation on nephropathy development mechanisms (blood
pressure, cardiovascular autonomic changes, renal GLUT2) in diabetic-hypertensive rats. Forty-one male spontaneously
hypertensive rats (SHR) ~250 g were injected with STZ or not; 30 days later, surgical renal denervation (RD) or sham
procedure was performed; 15 days later, glycemia and albuminuria (ELISA) were evaluated. Catheters were implanted
into the femoral artery to evaluate arterial pressure (AP) and heart rate variability (spectral analysis) one day later in
conscious animals. Animals were killed, kidneys removed, and cortical renal GLUT2 quantified (Western blotting).
Results: Higher glycemia (p < 0.05) and lower mean AP were observed in diabetics vs. nondiabetics (p < 0.05). Heart
rate was higher in renal-denervated hypertensive and lower in diabetic-hypertensive rats (384.8 ± 37, 431.3 ± 36,
316.2 ± 5, 363.8 ± 12 bpm in SHR, RD-SHR, STZ-SHR and RD-STZ-SHR, respectively). Heart rate variability was higher in
renal-denervated diabetic-hypertensive rats (55.75 ± 25.21, 73.40 ± 53.30, 148.4 ± 93 in RD-SHR, STZ-SHR- and RD-STZ-
SHR, respectively, p < 0.05), as well as the LF component of AP variability (1.62 ± 0.9, 2.12 ± 0.9, 7.38 ± 6.5 in RD-SHR,
STZ-SHR and RD-STZ-SHR, respectively, p < 0.05). GLUT2 renal content was higher in all groups vs.S H R .
Conclusions: Renal denervation in diabetic-hypertensive rats improved previously reduced heart rate variability.
The GLUT2 equally overexpressed by diabetes and renal denervation may represent a maximal derangement effect
of each condition.
Background
Autonomic neuropathy is a common complication of
diabetes mellitus that can be effectively reproduced in
animal models of diabetes: studies performed in our
laboratory in streptozotocin (STZ)-induced diabetic rats
showed that these animals present long-lasting changes
in blood pressure, heart rate and autonomic cardiovas-
cular reflexes [1-4]. Hypertension, a common morbid
condition associated with diabetes, can also have an
impact on cardiovascular reflexes [5]. The induction of
diabetes in spontaneously-hypertensive rats (SHR)
enhances abnormalities usually seen in both animal
models individually, i.e. spontaneous hypertension and
diabetes: using spectral analysis approaches, we demon-
strated decreased arterial pressure variability in diabetic
SHRs [6]. Moreover, the well-documented impairment
of heart rate baroreflex control previously observed in
SHR is further depressed in these rats [6].
Renal denervation caused by autonomic neuropathy
has been involved in the enhancement of kidney vulner-
ability to the hemodynamic effects of high blood pres-
sure in diabetic nephropathy [7,8]. This is caused by
decreased renal vascular resistance induced by decreased
sympathetic nerve activity, so that there would be no
opposition to diabetes and hypertension induced mesan-
gial cell stretch (9). Even though the STZ-diabetic rat
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any medium, provided the original work is properly cited.develops characteristic glomerulosclerotic lesions similar
to those found in human diabetic nephropathy [9], this
animal model does not develop systemic arterial hyper-
tension [3], thus, the association of hypertension when
SHR are made diabetic can approach this animal model
to human diabetic nephropathy [10,11].
It has been suggested that increased expression of
renal cortical GLUT1 (mesangial cells) [12], and GLUT2
(S1 tubular cells) [13] is involved in the development
and progression of diabetic nephropathy. The well-
known diabetes-induced GLUT2 overexpression and the
further rise that can be caused by hypertension [13] in
addition to hyperglycemia may lead to a further eleva-
tion in interstitial renal glucose concentration, and more
glucose is taken up by mesangial cells through GLUT1.
However, although we had already shown the effect of
denervation upon GLUT2 [14], this has not yet been
studied in diabetic-hypertensive rats.
Recently it was suggested that renal sympathetic
innervation plays a role in the pathogenesis of diabetic
nephropathy implying early enhancement in renal sensi-
tivity to intrarenal norepinephrine on diabetic renal
injury [15]. Since STZ-diabetes requires several months
to determine structural autonomic denervation of the
gastrointestinal tract [16] and of the heart [17], and no
data are available on renal denervation induced by dia-
betes, we propose surgical renal denervation in SHR
injected with STZ to evaluate the effects of renal dener-
vation on cardiovascular reflexes and markers of diabetic
nephropathy. The coexistence of diabetes and hyperten-
sion allows us to study the full effects of the failure of
autonomic innervation on renal function in an animal
model of diabetic nephropathy, with all its characteris-
tics as they occur in humans. This study aimed at exam-
ining the effects of renal denervation upon mechanisms
involved in the development of nephropathy (blood
pressure levels, cardiovascular autonomic changes
and renal glucose transporter GLUT2) in the STZ-SHR
animal.
Methods
Animals
The investigation followed the ethical rules established
by the G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r yA n i -
mals [18] and by the Colégio Brasileiro de Experimenta-
ção Animal (COBEA). The study was approved by the
Research Ethics Committee of Instituto de Cardiologia
do RS, protocol # UP: 3111/02. Experiments were per-
formed on 41 male SHR, weighing 240-270 g. Sample
size was calculated based on previous data from our
group [11]. All animals were bred and kept under stan-
dard laboratory animal house conditions at the Animal
Production and Research Unit of the Center for Scien-
tific and Technological Development of Fundação
Estadual de Produção e Pesquisa em Saúde do Rio
Grande do Sul, Brazil. They were fed with standard
balanced rat animal chow (12% protein content), given
water ad libitum, and kept in special plastic cages with
3-4 rats exposed to a 12-hour light and 12-hour dark
cycle (6 a.m./6 p.m.). Before all surgical procedures, rats
were premedicated with 2 mg kg
-1 butorphanol.
Diabetes induction of diabetes
Animals were acclimatized for 1 week, then fasted over-
night and rendered diabetic (STZ-SHR) by a single
injection of STZ (Sigma Chemical Co, St Louis, MO,
USA), 50 mg/kg in the tail vein. Streptozotocin was dis-
solved in citrate buffer (pH 4.5) and injected slowly.
Non-diabetic rats (SHR) were injected only with citrate
buffer. Diabetes was defined as a non-fasting glucose
>300 mg/dL in tail vein blood (test strips, Advantage,
Roche, Brasil), 48 h after STZ injection. Glycemia was
measured again at the end of all experiments.
Renal denervation
Thirty days after STZ injection, bilateral renal denerva-
tion or sham surgery was performed in the 4 experi-
mental groups: renal-denervated diabetic (RD-STZ-SHR,
n = 11), diabetic (STZ-SHR, n = 11), renal-denervated
hypertensive (RD-SHR, n = 10) and hypertensive (SHR,
n = 9), under ketamine (90 mg/kg) and xylasine (10 mg/
kg) anesthesia, i.p.. Renal denervation was accomplished
by using a surgical-pharmacological procedure adapted
as previously described and validated in our laboratory
[14]. Mechanical denervation was performed by carefully
stripping all visible nerves, at 16 × magnification (M90
stereomicroscope, FD Vasconcelos), along the renal
arteries and veins from the aorta to the hilum of the
kidney. Chemical denervation was performed by quickly
painting the renal artery with 20% phenol in absolute
ethanol. Then, the artery was washed with isotonic
saline. For sham denervation, the surgical procedure was
the same, but the renal artery and vein were not isolated
and the nerves were left intact.
Fifteen days after the surgical procedure (45 days after
the STZ injection) 24 h urine was collected in metabolic
cages for glucose, sodium and albumin measurements.
After all protocols, the final sample size was: RD-STZ-
SHR, n = 5, STZ-SHR, n = 6, RD-SHR, n = 6 and SHR,
n=7 .
Acquisition of cardiovascular variables
Catheters filled with saline were implanted into the
femoral artery(PE-10), under ketamine and xylasine
anesthesia for direct measurement of arterial pressure
(AP). One day after catheter placement, the arterial
cannula was connected to a strain-gauge transducer
(P23Db, Gould-Statham, Oxnard, CA) and blood pressure
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microcomputer equipped with an analog-to-digital con-
verter board (CODAS, 2-kHz sampling frequency, Dataq
instruments, Inc., Akron, OH). Rats were conscious and
moved freely during the experiments. Recorded data were
analyzed on a beat-to-beat basis.
Assessment of autonomic control - Spectral analysis
Time series of pulse intervals (PI, tachograms) and sys-
tolic AP (SAP, systograms) were obtained from blood
pressure records. Stationary fragments with about 300
beats, coincident in tachogram and systogram, were
selected and spectral analysis was performed using an
autoregressive model. The spectral bands for rats (very
low frequency, VLF: 0.0-0.2 Hz, low frequency, LF: 0.2-
0.75 Hz, high frequency, HF: 0.75-3.0 Hz) were defined
according to previous references [19]. Tachogram and
systogram spectra, for each stationary fragment, were
evaluated quantitatively and values of HR variability
(HRV) and SAP variability (SAPV) were obtained.
Among the parameters obtained by spectral analysis,
those distinguished for their physiological significance
are the relationship between the powers of LF and HF
components of HRV - the LF/HF index - or sympa-
thetic-vagal balance [20], and the absolute powers of the
LF and VLF components of SAPV, related to vascular
sympathetic modulation and to renin-angiotensin system
modulation on SAP [21]. Moreover, a relationship
expressed by the root of the ratio between the absolute
powers of LF components of HRV and VPAS - the LF
alpha index - is known to express spontaneous barore-
flex sensitivity [22].
Renal harvesting
After cardiovascular evaluation (45 days of diabetes
duration, 15 days after renal denervation), the rat kid-
neys were removed for cortical GLUT2 protein content
evaluation. The rats were anesthetized with sodium pen-
tobarbital (25 mg/kg body weight, iv), their kidneys were
perfused with Hanks’ buffer to eliminate the intravascu-
lar blood content, and removed. Renal outer cortex was
carefully dissected and 1.5 mm slices were weighed and
frozen at -70°C for further analysis.
Laboratory measurements
Urinary glucose was measured using the colorimetric
enzymatic test (commercial kit, Merck, Darmstadt, Ger-
many, Centrifichem System 400-Roche/Cobas Mira-
Roche). Urinary sodium concentrations were determined
using an indirect ion selective electrode (ISE) together
with the Mega-Bayer auto-analyzer. Samples for urinary
albumin were collected without preservatives and stored
at -70°C after centrifugation. Albuminuria was measured
by a quantitative direct competitive enzyme-linked
immunoabsorbant assay (ELISA) (Nephrat, Exocell Inc,
Philadelphia, PA, USA) using a highly specific anti-rat
albumin antibody. The quantification range for albumi-
nuria was 0.156-10 mg/dl. Samples were diluted 1:2.
Results were expressed in mg/24 h.
GLUT2
Renal cortex GLUT2 protein expression was analyzed by
Western blot following standard protocols with com-
mercially acquired antibody (Chemicon International
Inc., Temecula, CA, USA) [23]. Tissue samples were
homogenized in 10 w/v buffer (10 mM) Tris-HCl, 1
mM EDTA, and 250 mM sucrose, pH 7.4, containing 5
mg/mL aprotinin, and centrifuged at 3000 g for 15 min.
The supernatant was centrifuged at 12,000 g for 20 min,
and the pellet was re-suspended as a plasma membrane
enriched fraction (PM) [23]. Briefly, equal amounts of
membrane protein (100 μg from medulla and 150 μg
from cortex samples) were subjected to SDS-PAGE
(10%) and transferred to nitrocellulose membrane by
electrophoresis. After blocking with non-fat-milk, the
sheets were incubated with the specific antiserum, fol-
lowed by washing and incubation with (
125I)-protein A
(Amersham Biosciences UK Limited, Buckinghamshire,
UK). After a final wash, the nitrocellulose sheets were
dried at room temperature, and exposed to X-ray film
for 5 days at -70°C. The blots were quantified by densi-
tometric analysis, using the ImageQuant TLsoftware
(Amersham Biosciences, Buckinghamshire, UK Pharma-
cia Biotech, Sweden). The results were normalized con-
sidering the mean of the values of control animals
(SHR) in each membrane as 100, and reported as arbi-
trary units (AU). Loading control was performed by
densitometry of Coomassie-stained gel [24].
All data obtained are reported in compliance with the
ARRIVE guidelines on animal research [25].
Statistical Analysis
Data are reported as means ± SEM. Statistical signifi-
cance was analyzed by two-way analysis of variance
(ANOVA), post-hoc Student-Newmann-Keuls. Urinary
albumin data were log-transformed before analysis. Sig-
nificance was defined at the 0.05 level. The Statistical
Package for Social Sciences (version 15.0, SPSS, Chicago,
Illinois) was used for data analysis.
Results
General characteristics of the animals studied at baseline
and 45 days after the STZ injection are shown in Table
1. Body weights were similar in all experimental groups
at baseline (~266 ± 21 g, p = 0.729). Forty-five days
after diabetes induction, STZ-SHR did not gain weight
as the non-diabetic rats did. Therefore, the SHR and
RD-SHR were heavier than STZ-SHR and RD-STZ-SHR
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affect weight gain in any of the groups studied (p =
0.249).
Glycemia was elevated ~4 fold, two and 45 days after
STZ injection in STZ-SHR and RD-STZ-SHR when
compared to SHR and RD-SHR groups (p < 0.001).
A l s o ,2 4 - hd i u r e s i sa sw e l la s2 4 - hu r i n a r ye x c r e t i o no f
glucose, and sodium were higher in diabetic animals
versus SHR and RD-SHR (p < 0.001) 45 days after STZ
injection, confirming the severity of the diabetic state
obtained. Renal denervation did not affect urinary glu-
cose (p = 0.236), natriuresis (p = 0.680) and diuresis
(0.398). Urinary albumin was higher in the diabetic
groups (p < 0.001) vs SHR and RD-SHR and also higher
in the HRD vs SHR group (p = 0.013). However, renal
denervation did not cause additional albuminuria in RD-
STZ-SHR as compared to STZ-SHR (Table 1).
Table 2 shows the cardiovascular parameters. Mean
AP was ~20% lower in STZ SHR vs. SHR, with no dif-
ference among the other groups. Systolic and diastolic
AP were lower in group STZ-SHR vs.S H R ,P<0 . 0 5 .
Diastolic AP was ~18% lower in group RD-STZ-SHR vs.
RD-SHR (P < 0.05). Heart rate was ~ 12% higher in RD-
SHR vs. SHR and ~18% lower in STZ-SHR vs. SHR. The
RD-STZ-SHR group presented a lower heart rate as
compared to the RD-SHR group and higher than the
STZ-SHR group (p < 0.05).
Heart rate variability and SAPV are shown in table 2.
Heart rate variability was similar between groups, but
was higher in the RD-STZ-SHR vs. RD-SHR and STZ-
SHR groups. The LF component of HRV, in absolute
units (ms
2), was increased by renal denervation in dia-
betic animals (p < 0.05, RD-STZ-SHR vs.R D - S H Ra n d
STZ-SHR group), accompanying the increase of total
HRV. In normalized units (nu), the LF component was
reduced by diabetes (STZ-SHR vs. SHR group, p < 0.05)
which was offset in the diabetic group after renal
denervation, since there was no difference among
groups. The HF component of HRV in absolute units
(ms
2) was increased by diabetes (SHR vs.S T Z - S H R
group, p < 0.05, RD-SHR vs. RD-STZ-SHR, p < 0.05),
with no reduction in hypertensive rats after renal dener-
vation (SHR vs. RD-SHR group). In normalized units
(nu), HF component was higher in diabetic rats (SHR
vs. STZ-SHR group, p < 0.05), with no differences
among the other groups. Sympathetic-vagal balance was
decreased by diabetes (SHR vs.S T Z - S H Rg r o u p ,p<
0.05), only in the non-denervated group. SAPV was
r e d u c e d4 - f o l db yd i a b e t e s( S H Rv s .S T Z - S H R ,p<
0.05), but did not differ among the other groups. The
LF component of SAPV was shown to be diminished by
diabetes and renal denervation (STZ-SHR and RD-SHR
vs. SHR, p < 0.05) and increased when diabetes was
associated with renal denervation (RD-STZ-SHR vs.
RD-SHR, p < 0.05). The HF component of SAPV was
enhanced by diabetes (SHR vs.S T Z - S H R ,p<0 . 0 5 ,
RD-SHR vs. RD-STZ-SHR, p < 0.05), with no difference
observed between the SHR and RD-SHR groups. The
alpha index, which estimates the spontaneous cardiac
baroreflex sensitivity, was higher in STZ-SHR vs.S H R
(P < 0.05).
Renal cortical GLUT2 was higher in RD-SHR, STZ-
SHR and RD-STZ-SHR vs. SHR (99.9 ± 14, 185.6 ± 13,
182.7 ± 21, 201.4 ± 25 UA, p = 0.004). Thus, both renal
denervation and diabetes caused GLUT2 overexpression,
and their association did not induce additional changes.
Discussion
The association of experimental hypertension, diabetes
and surgical renal denervation can compose the picture
we expect to see in long-term diabetes, as neuropathy
and nephropathy are associated in a milieu where hyper-
glycemia and hypertension usually coexist. Here we
showed the result of the association of the three
Table 1 General characteristics of animals studied
SHR
(n = 9)
RD-SHR
(n = 7)
STZ-SHR
(n = 9)
RD-STZ-SHR
(n = 5)
P
(Denervation)
P
(Diabetes)
P
(Interaction)
Initial weight (g) 258 ± 14 267 ± 29 269 ± 13 272 ± 28 0.452 0.278 0.729
Weight 45 days after STZ injection (g) 310 ± 28 322 ± 35 275 ± 53* 223 ± 71# 0.249 <0.001 0.068
Initial plasma glucose (mg/dl) 84.4 ± 7 91.2 ± 5 414.1 ± 135* 357.4 ± 124# 0.463 <0.001 0.352
Plasma glucose 45 days after STZ
injection (mg/dl)
92.0 ± 14 91.1 ± 9 417.5 ± 114* 388.0 ± 48# 0.548 <0.001 0.571
Diuresis (mL/24 h) 11.2 ± 4 20.7 ± 7 96.9 ± 42* 103.3 ± 38# 0.398 <0.001 0.872
24-h urinary glucose (mg/24 h) 0.37 ± 0.4 0.23 ± 0.4 758.0 ± 544* 1019.0 ± 379# 0.236 <0.001 0.235
24-h urinary sodium (mEq/24 h) 1.03 ± 0.3 1.29 ± 0.8 4.38 ± 2.1* 4.50 ± 1.8# 0.680 <0.001 0.881
24-h urinary albumin (mg) 152 [111-
341]
711* [273-
1304]
2456* [1491-
3982]
1538# [667-2988] 0.472 <0.001 <0.001
Data are shown as mean ± SEM. SHR: spontaneously hypertensive rats; RD-SHR: renal-denervated spontaneously hypertensive rats; STZ-SHR: diabetic
spontaneously hypertensive rats; RD-STZ-SHR: diabetic renal-denervated spontaneously hypertensive rats; n = indicates the number of animals. *P < 0.001 vs. H;
#P < 0.01 vs. HRD; (Two-way ANOVA; post hoc: Student Newman Keuls). For the variables diuresis, urinary glucose, and urinary sodium the n is 9, 10, 11 and 11,
respectively.
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an animal model very close to long-standing human dia-
betes. The most important findings were: 1. surgical
renal denervation did not change the baseline conditions
of diabetes and hypertension significantly since the ani-
mals submitted to this procedure maintained high AP
and glycemia; 2. heart rate and systolic AP variability
were negatively affected by diabetes associated with
hypertension, but renal denervation could compensate
partially for these derangements; 3. diabetes and renal
denervation could similarly cause overexpression of
renal cortical GLUT2, with no additional effect of one
condition upon the other; 4. albuminuria raised by the
effect of diabetes and by the effects of renal denervation
separately; high albuminuria already induced by dia-
betes/hypertension was not additionally affected by
denervation in these animals.
The animal model(diabetic-hypertensive)
It should first be mentioned that both the diabetic state
induced by STZ (hyperglycemia, low body weight) and
the hypertensive state (high AP levels) were maintained
in renal-denervated rats,a sw ep r e v i o u s l ys h o w e d
[13,14].
Although different from previous data from our group
[11], the association of diabetes in the SHR slightly
reduced mean AP, a finding that was previously
reported by others [26], and could be explained by the
low AP levels usually determined by STZ-diabetes [3].
However, AP values were still kept at hypertensive levels
in the diabetic-SHR.
Cardiovascular changes in renal denervated diabetic-
hypertensive rats
Bradycardia was observed in diabetic rats, as previously
described [1,3,4,6], but the interesting and new finding
is that renal denervation increased the heart rate even in
the diabetic-SHR. Almost all animal models of hyperten-
sion are characterized by hyperactivity of the sympa-
thetic renal system [27,28]. Previous study by our group
showed a heart rate reduction induced by bilateral renal
denervation in hypertensive rats, but the hypertension
was of short duration and was induced by aortic ligation
[29]. In the present study, the tachycardia presented by
RD-SHR was accompanied by a reduction in the sympa-
thetic vascular modulation, which could be due to the
lowered total vascular resistance previously described in
renal-denervated SHR [30].
Table 2 Cardiovascular parameters: Heart rate variability (HRV) and systolic arterial pressure variability (SAPV)
analysis
SHR (n = 7) RD-SHR (n = 6) STZ-SHR (n = 6) RD-STZ-SHR (n = 5)
Heart rate (bpm) 384.82 ± 37.26 431.32 ± 36.60* 316.21 ± 5.17* 363.81 ± 12.25§#
Systolic AP (mmHg) 178.43 ± 16.07 171.03 ± 5.22 145.39 ± 8.49* 157.20 ± 26.41
Diastolic AP (mmHg) 141.17 ± 19.10 150.27 ± 13.52 116.26 ± 29.34* 118.88 ± 10.75#
Mean AP (mmHg) 160.13 ± 16.08 165.25 ± 8.89 129.22 ± 5.66* 139.90 ± 9.15#
HRV
HRV (ms
2) 69.84 ± 37.91 55.75 ± 25.21 73.40 ± 53.30 148.39 ± 93.58§#
LF peak (Hz) 0.64 ± 0.06 0.69 ± 0.08 0.55 ± 0.10 0.54 ± 0.14#
LF absolute (ms
2) 5.17 ± 5.24 1.62 ± 0.98 2.12 ± 0.97 7.38 ± 6.52§#
LF nu 26.84 ± 19.05 26.07 ± 13.63 6.98 ± 3.86* 16.58 ± 7.99
HF (Hz) 2.42 ± 0.58 2.12 ± 0.82 2.00 ± 0.56 2.31 ± 0.65
HF absolute (ms
2) 14.56 ± 12.83 4.14 ± 3.09 32.11 ± 15.88* 37.22 ± 20.54#
HF nu 73.16 ± 19.05 72.90 ± 12.59 93.02 ± 3.86* 83.42 ± 7.99
LF/HF Índex 0.47 ± 0.47 0.49 ± 0.32 0.08 ± 0.05* 0.21 ± 0.11
SAPV
SAPV (mmHg
2) 68.33 ± 36.16 61.89 ± 24.84 15.61 ± 10.26* 29.86 ± 20.69
VLF (mmHg
2) 77.13 ± 54.27 38.00 ± 27.50 12.91 ± 8.11* 46.20 ± 47.03
LF (Hz) 0.44 ± 0.06 0.53 ± 0.06 0.36 ± 0.07* 0.40 ± 0.08
LF absolute (mmHg
2) 18.49 ± 18.17 3.69 ± 3.10* 1.38 ± 1.38* 56.61 ± 26.75#
HF peak (Hz) 1.72 ± 0.68 2.12 ± 0.56 1.19 ± 0.22 1.52 ± 0.48
HF absolute (mmHg
2) 4.67 ± 5.09 53.94 ± 17.65* 5.66 ± 5.45 6.27 ± 10.70#
aLF Índex 0.54 ± 0.16 0.86 ± 0.56 1.44 ± 0.38* 1.73 ± 1.38
Data are shown as mean ± SEM. SHR: spontaneously hypertensive rats; RD-SHR: renal denervated spontaneously hypertensive rats; STZ-SHR: diabetic
spontaneously hypertensive rats; RD-STZ-SHR: diabetic renal-denervated spontaneously hypertensive rats; AP: arterial pressure; n = indicates the number of
animals. VLF: very low frequency; LF: low frequency; HF: high frequency. *P < 0.05 vs. H, § P < 0.05 vs. D e #P < 0.05 vs. HRD. (Two-way ANOVA; post hoc:
Student Newman Keuls).
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approaches, we observed that the LF component, in nor-
malized units (nu), was reduced and the HF component,
also in nu, of heart rate variability was elevated by dia-
betes, the former more than the latter. Thus the net
effect was that the sympathovagal balance was reduced
in these rats, which was also shown in non-hypertensive
diabetic rats [31]. Again, renal denervation compensated
this derangement, resulting in a sympathovagal balance
almost at the levels of the controls (SHR). Concerning
total heart rate variability, it was not reduced by dia-
betes, as we previously showed [6]; decreased heart rate
variability was reported only after long periods of dia-
betes in normotensive rats [32-34]. Interestingly, again
renal denervation was able to improve this cardiovascu-
lar derangement: diabetic-SHR denervated rats had the
highest total heart rate variability. This was observed
considering the comparisons of RD-STZ-SHR vs STZ-
SHR and also RD-STZ-SHR vs SHR, showing an inter-
action between the diabetes and denervation factors in
hypertensive rats. Although denervation could not
change HRV in the nondiabetic rats, in diabetics this
intervention was able to increase HRV. Heart rate varia-
bility is classically reduced in hypertension, diabetes and
heart failure, resulting in additional cardiovascular risk
to these individuals [19]. It is known that AP reduction
can improve autonomic dysfunction in hypertensive
individuals [35], but this is not the case, despite
improved HRV, since RD-STZ-SHR and STZ-SHR had
similar AP levels. The present results showed improved
autonomic control by denervation in diabetic rats, a
finding that supports the importance of the renal sym-
pathetic nervous system in cardiac sympathetic and
parasympathetic control.
On the other hand, the LF component of arterial pres-
sure variability decreased in the diabetic-SHR, as pre-
v i o u s l ys h o w ni nt h es a m ea n i m a lm o d e l[ 6 ]a n di n
normotensive rats [3,4]. As the low frequency oscilla-
tions of blood pressure correspond to the influence of
the sympathetic fibers acting on the cardiovascular sys-
tem [36-38], this reduced sympathetic influence on
blood vessels could explain, at least in part, the non-sig-
nificant slightly lower blood pressure and its variability
observed in the diabetic-SHR. Renal denervation raised
arterial pressure variability, although not to the hyper-
tensive group levels. Indeed, the changes in the LF com-
ponent of systolic AP variability could result from
changes in sympathetic outflow to different vascular
beds in response to total nerve denervation, which
includes abolishing afferent activity [39]. However,
opposite effects of denervation upon the sympathetic
influence on blood vessels occurred in hypertensive and
hypertensive-diabetic rats. In the hypertensive group,
denervation determined lower vascular sympathetic
modulation, while in the diabetic group, vascular sympa-
thetic modulation was raised. Accordingly, the reduction
of AP observed only in diabetics may have contributed
to these differences. Moreover, the effects of cardiopul-
monary afferents on peripheral sympathetic activity,
especially in the kidney, may have contributed to this
increase in sympathetic modulation since in diabetic
animals this reflex control is blunted [40]. Similarly,
spontaneous baroreflex, evaluated by the aLF index was
improved in diabetic rats, renal-denervated or not, prob-
ably accompanying their blood pressure levels, which
were slightly lower than in the other rats. Baroreflex
sensitivity was previously studied in STZ-induced dia-
betic rats, showing contradictory results, probably
because of different diabetes duration [31,41] and eva-
luation methods [42].
Renal changes in renal denervated diabetic-hypertensive
rats
Renal cortical GLUT2, a marker of diabetes-induced
renal injury [10,11] was raised by diabetes and denerva-
tion independently. These effects were not more intense
when both conditions were associated (in the RD-STZ-
SHR group), confirming previous data showing the sym-
pathetic modulation of the expression of this glucose
transporter [13]. The lack of additional regulation by the
association of denervation/diabetes could be due to the
fact that GLUT2 expression is already increased in SHR,
as compared to Wistar rats [10], and diabetes and
denervation induced further increase in GLUT2 expres-
sion, which might achieve such high maximal transcrip-
tional and translational activity that the association
could not increase it any more. GLUT2 changes were
not accompanied by changes in urinary glucose, natriur-
esis and diuresis, as previously shown by us in normo-
tensive rats [13,43,44], where we raised the possibility of
a causal relationship between these variables. Again, this
difference may be related to SHR, instead of Wistar rats,
and further investigation of SGLT2 expression and cel-
lular location of GLUT2 could clarify the relationship
between GLUT2 and glycosuria and natriuresis. In addi-
tion, the absence of expected denervation diuresis and
natriuresis in SHR [27] may be related to the increase in
renal responsiveness to norepinephrine and angiotensin
II under this condition in which the magnitude of renal
nerve effects may be decreased [45].
An association between diabetic neuropathy and
nephropathy by a possible effect of enhancing kidney
vulnerability to the hemodynamic effects of blood pres-
sure was suggested by a possible effect of denervation in
determining an enhancement of kidney vulnerability to
the hemodynamic effects of blood pressure [7]. How-
ever, renal denervation did not change albuminuria in
diabetic rats, only in hypertensive nondiabetic rats.
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Page 6 of 8Thus, acceleration of diabetic nephropathy cannot be
ascribed to it, as previously shown in normotensive rats
[14], possibly because the amount of time rats were
maintained denervated (only 14 days) could be insuffi-
cient to induce significant glomerular structural changes.
Moreover, perhaps maximal injury was caused by hyper-
glycemia in diabetic rats, thus renal denervation could
not exacerbate the glomerular damage which actually
occurred in hypertensive rats not subjected to hypergly-
cemia, only to the hemodynamic effects of kidney vul-
nerability when there are high systemic levels of arterial
pressure.
Interestingly, both GLUT2 and albuminuria followed
the same direction in the animal model studied: they
were raised by the diabetic and hypertensive states, and
renal denervation did not have any additional effect
upon both variables. Considering the following possible
sequence of events previously suggested [13], high sym-
pathetic tonus associated with hyperglycemia leads to
overexpression of GLUT2, increased glucose reabsorp-
tion, higher interstitial concentrations of glucose, more
glucose available to mesangial cells, GLUT1 overexpres-
sion [12], higher glucose uptake by mesangial cells and,
finally, acceleration of the well-known intracellular steps
involved in the pathogenesis of diabetic nephropathy.
Some limitations in the current study should be
pointed out. Differences in sample size for different vari-
ables presented are related to the high mortality rates
presented by these animals which was previously shown
by others [46] and ascribed to the toxicity of STZ in
addition to the hard surgical intervention (renal dener-
vation) performed in the present study. It is possible
that the healthiest rats survived, influencing the final
results. Another possible limitation is that renal dener-
vation could determine different results according to the
animal model used, age and timing of the evaluation
performed [6,29,31,41,42]. Indeed, some differences pre-
sented in this study as compared to others could be
accounted for these differences.
Conclusions
We conclude that the GLUT2 equally overexpressed by
diabetes and renal denervation may represent a maximal
derangement effect of each condition. The differences to
previous studies could possibly be ascribed to the
unique condition presented here, of diabetes associated
with sympathetic hyperactivity and renal denervation.
Renal denervation in this particular condition, which we
think is the closest we have to the human condition, is
characterized by the amelioration of previously reduced
heart rate and heart rate variability, thus counterbalan-
cing the previous high risk condition. As recently shown
in a proof-of-principle study in patients with hyperten-
sion resistant to conventional therapy, where the renal
denervation procedure proves to be safe and produces
sustained lowering of arterial pressure [47], there could
be other long-term benefits from the procedure, but
they cannot yet be confirmed with the present results.
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